<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T04:16:57Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/21386" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/21386</identifier><datestamp>2026-09-24T22:24:38Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Mishra, Ram</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Molinaro, Luke</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Neuroscience</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2017-05-08T15:48:20Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2017-05-08T15:48:20Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2017-06</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/21386</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/7784</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">It has been estimated that approximately 300,000 Canadians are afflicted with&#xd;
schizophrenia (SCZ). Due to the severity of symptoms as well as critical age of onset, the quality of life among SCZ patients can be poor; thus, further therapeutic research is of great interest. In addition to the more-common rodent models of SCZ (amphetamine sensitization, PCP sensitization, etc.), our lab has proposed the medial prefrontal cortex (mPFC) synapsin-II knockdown&#xd;
(KD) model. Prior to this study, the cognitive effects of mPFC synapsin-II KD had yet to be&#xd;
reported. Using a 14-day continuous infusion of antisense (AS) deoxyoligonucleotides for&#xd;
synapsin-II to the mPFC, the results of the KD model have been recreated for further study. The 5-choice-serial-reaction-time-task was utilized to determine the effects of mPFC synapsin-II KD on attention and vigilance. In addition to reductions in both PPI (p&lt;0.05) and social interaction&#xd;
(p&lt;0.05), as well as hyper-locomotion (p&lt;0.05); rats treated with synapsin II AS performed&#xd;
significantly worse on the 5-CSRTT than did control (mismatch/aCSF) animals. The AS animals&#xd;
were significantly less likely to make correct responses (p&lt;0.001), and significantly more likely to commit omissions (p&lt;0.0001) and perseverative responses (p&lt;0.05) than were control animals.&#xd;
Additionally, an [18F]FDG tracer and PET/CT scans were used to determine differences&#xd;
in brain metabolism due to synapsin-II KD. Results revealed significant reductions in [18F]FDG among AS treated rats (p&lt;0.05) when compared to control animals. This reduction appeared to be a global result, however it followed 13-days of treatment which may account for the widespread effect. The mPFC synapsin-II KD model of SCZ has showcased cognitive and metabolic effects similar to that of SCZ. These findings, in conjunction with past research, provide evidence for the synapsin-II KD model as a viable rodent model of SCZ. Further research utilizing this model will provide valuable insight into the pathogenesis of SCZ and potential therapeutics.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Master of Health Sciences (MSc)</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Schizophrenia</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Dopamine</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Rodent Model</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Hyperfrontality</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">THE EFFECTS OF SYNAPSIN II KNOCK-DOWN IN THE RAT MEDIAL PREFRONTAL CORTEX ON ATTENTION</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>